Immunotherapy before and after surgery shows promise for lung cancer
NCT ID NCT07450183
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests the drug cemiplimab, an immunotherapy, given before and after surgery for people with early-stage non-small cell lung cancer that has high levels of a protein called PD-L1. About 33 participants will receive cemiplimab for three cycles, then undergo surgery, followed by ten more cycles. The main goal is to see how many patients have no cancer left in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab
What this could lead to
If successful, this could show that adding cemiplimab around surgery helps control lung cancer and may improve long-term outcomes.
What could go wrong
This is a small, early-phase trial with only 33 participants. It may not prove effective, and side effects from immunotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henry Ford Health
Detroit, Michigan, 48202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••